Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured Article The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Author: Chris Markoch. Posted: 1/18/2026. 
Key Takeaways - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That often means targeting companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these firms will never survive or scale, but if one does deliver, investors can see outsized returns. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While popularity is no guarantee of success, it can give an investor added conviction in a stock's potential. While headlines are dominated by political noise, one of the most important financial stories in the world is going virtually unreported. A new documentary reveals a paradigm-shifting technological breakthrough that could underpin the next era of innovation — and potentially create enormous wealth for early investors.
This isn't AI, crypto, or quantum computing. It's something far more foundational — a core technology already shaping today's advances and expected to define the future. Major investors and tech leaders are quietly pouring billions into it, fully aware that history shows these revolutions reward the prepared and punish the careless.
The documentary also explains the risks: why owning the wrong companies — or buying the right ones at the wrong time — could be devastating. To understand what's really happening, and how investors may be able to position intelligently, you can watch the full film here. Click here to see the full documentary Some investors broaden the definition of a penny stock to include any share trading for $5 or less. This screener, however, follows the traditional definition: stocks trading below $1. These names are highly volatile—do your own research and be clear on your risk tolerance before opening a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative approach. If the company secures FDA approval and can scale manufacturing and distribution, its oral vaccines could reduce logistical barriers for mass immunization campaigns and create significant licensing opportunities. Positive trial results or a commercial collaboration could rapidly shift sentiment and valuation given the stock's current low base. Clinical risk remains the biggest challenge. Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst coverage for Vaxart is sparse—only a single analyst follows the stock—which should prompt additional caution for investors. Additionally, VXRT shows about 18% institutional ownership. On a more positive note, the stock has roughly 2% short interest, which may limit some downside volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software solutions enable the precise 3D mapping required for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on two things: continued progress toward vehicle automation and the potential for partnerships with major automakers. If the company can demonstrate superior performance or a clear cost advantage, it could secure supply agreements or licensing deals that materially improve revenue visibility. Microvision's technology may also find applications in robotics and smart-city projects, providing additional growth optionality. Despite the promise, Microvision faces stiff competition from LiDAR specialists such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and recurring delays in LiDAR adoption have frustrated investors. MVIS is covered by three analysts and has a consensus price target of $2.50—a roughly 169% upside from its Jan. 15 close. However, like many speculative names, Microvision displays relatively low institutional ownership (around 30%) and elevated short interest (about 21%), signaling potential for high volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and enable monetization opportunities that traditional systems overlook. The bullish thesis for Datavault AI lies in its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses—and potentially individuals—are seeking ways to safely monetize digital information. Datavault's platform could benefit from growing AI adoption and increased attention to data sovereignty. Early-stage traction or strategic partnerships might catalyze investor confidence. Still, Datavault AI operates in a highly experimental space. Its business model is evolving, and the path to meaningful revenue growth remains unproven. Institutional ownership is under 1%, and short interest exceeds 16% as of this writing. Investors considering DVLT should view it as a long-term, speculative position based on belief in the data-as-an-asset thesis rather than near-term earnings potential.
| 
